Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.27)
# 367
Out of 4,840 analysts
231
Total ratings
41.04%
Success rate
20.12%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $2.81 | +469.40% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $6.44 | +55.28% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $10.25 | +192.68% | 6 | May 14, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $8.65 | +189.02% | 2 | May 14, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $45.93 | +143.85% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $18.95 | +21.37% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $37.90 | +113.72% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.75 | +154.55% | 16 | Apr 28, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $76.89 | +59.97% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $90 | $3.10 | +2,803.23% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.24 | +212.50% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $47.41 | +178.42% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $20.42 | +22.43% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $35.66 | +230.90% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $32.11 | +12.11% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $20.36 | +229.08% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $6.22 | +237.62% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $9.49 | +205.58% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $2.35 | +623.40% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $0.79 | +912.27% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $15.16 | +282.59% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.40 | +358.33% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $6.42 | +180.37% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.90 | +636.84% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.53 | +413.83% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.64 | +1,180.49% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.70 | +758.74% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.60 | +1,150.00% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.00 | +666.67% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.25 | +71,900.00% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.54 | +7,436.76% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $2.99 | +13,277.93% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.82 | +10,291.20% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.79 | +2,550.96% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.37 | +3,196.70% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.93 | +1,081.78% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.14 | +5,163.16% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.18 | +7,527.12% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.39 | +181,194.96% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.52 | +30,752.29% | 1 | Jan 9, 2020 |
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $2.81
Upside: +469.40%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $6.44
Upside: +55.28%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $10.25
Upside: +192.68%
Zevra Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $25
Current: $8.65
Upside: +189.02%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $45.93
Upside: +143.85%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $18.95
Upside: +21.37%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $37.90
Upside: +113.72%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.75
Upside: +154.55%
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $76.89
Upside: +59.97%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.10
Upside: +2,803.23%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.24
Upside: +212.50%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $47.41
Upside: +178.42%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $20.42
Upside: +22.43%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $35.66
Upside: +230.90%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $32.11
Upside: +12.11%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $20.36
Upside: +229.08%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $6.22
Upside: +237.62%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $9.49
Upside: +205.58%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $2.35
Upside: +623.40%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $0.79
Upside: +912.27%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $15.16
Upside: +282.59%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.40
Upside: +358.33%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $6.42
Upside: +180.37%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.90
Upside: +636.84%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $2.53
Upside: +413.83%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.64
Upside: +1,180.49%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.70
Upside: +758.74%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.60
Upside: +1,150.00%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.00
Upside: +666.67%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.25
Upside: +71,900.00%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.54
Upside: +7,436.76%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $2.99
Upside: +13,277.93%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.82
Upside: +10,291.20%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.79
Upside: +2,550.96%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.37
Upside: +3,196.70%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.93
Upside: +1,081.78%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.14
Upside: +5,163.16%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.18
Upside: +7,527.12%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.39
Upside: +181,194.96%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.52
Upside: +30,752.29%